There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, ...

The mergers and acquisitions market has already seen a flurry of deals at the start of 2025 across sectors. Here's a look at ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

Next-gen obesity biotech Metsera has filed to debut on the public markets, proposing an IPO nine months after emerging. | ...

leadership skills and extensive experience across the interior Eli Cox is a four-year starter at center and right guard with most time spent at the former including 12 starts in 2024 inside ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

County Public Schools has joined dozens of other school systems and institutions in suing pharmaceutical and pharmacy companies, alleging that the companies manipulated the prices of insulin and other ...

Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...

Kristin Sherman leads startup Kovina Therapeutics, which is still in the early stages of developing ways to stop human ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...